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Background: People with Familial Hypercholesterolemia (FH) may benefit from lifestyle changes supporting their
primary treatment of dyslipidaemia. This project evaluated the efficacy of an individualised tailored lifestyle intervention
on lipids (low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC)
and triglycerides), systolic blood pressure, glucose, body mass index (BMI) and waist circumference in people with FH.
Methods: Adults with FH (n= 340), recruited from a Dutch cascade screening program, were randomly assigned to
either a control group or an intervention group. The personalised intervention consisted of web-based tailored lifestyle
advice and personal counselling. The control group received care as usual. Lipids, systolic blood pressure, glucose, BMI,
and waist circumference were measured at baseline and after 12 months. Regression analyses were conducted to
examine differences between both groups.
Results: After 12 months, no significant between-group differences of cardiovascular disease (CVD) risk indicators were
observed. LDL-C levels had decreased in both the intervention and control group. This difference between intervention
and control group was not statistically significant.
Conclusions: This project suggests that an individually tailored lifestyle intervention did not have an additional effect in
improving CVD risk indicators among people with FH. The cumulative effect of many small improvements in all
indicators on long term CVD risk remains to be assessed in future studies.
Trial registration: NTR1899 at ww.trialregister.nlBackground
Familial hypercholesterolemia (FH) is an autosomal dom-
inant disorder of the lipoprotein metabolism. Due to a de-
fect of the low density lipoprotein (LDL) receptor gene,
plasma concentrations of LDL cholesterol (LDL-C) are ele-
vated [1]. In the Netherlands, approximately one in 500
people is affected with the heterozygous type of FH [2].* Correspondence: mnm.vanpoppel@vumc.nl
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distribution, and reproduction in any mediumElevated serum LDL-C and therefore FH is associated
with an elevated risk of premature cardiovascular dis-
ease (CVD)[3], which is the disease with the highest bur-
den in disability adjusted life years in the Netherlands
[4]. If elevated LDL-C is not diagnosed and treated, the
cumulative risk of developing coronary artery disease
(CAD) by the age of 60 years is over 60% for men, and
over 30% for women [5]. Large primary and secondary
prevention trials with statins have clearly demonstrated the
benefit of reducing LDL-C in subjects with high LDL-C
[6,7]. Also, Versmissen and colleagues showed an overall
risk reduction in a large cohort (n= 2146) of people withntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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despite effective LDL-C lowering statin treatment [9].
Apparently, lifestyle factors can play an important role in
moderating the course of this disorder [10,11], as is under-
lined by the EUROASPIRE III survey, conducted in 2006–
2007 in 22 European countries. This survey showed a high
prevalence of unhealthy lifestyles among CVD patients
treated by cardiologists, and moreover, that use of medica-
tion was often inadequate to achieve treatment goals [12].
Results of primary prevention trials in high-risk persons
and secondary prevention trials in CVD patients both
show that substantial reductions in the CVD risk can be
obtained through lifestyle changes [13,14]. For example,
the INTERHEART study showed that eating fruit and
vegetables daily, being physically active regularly and
avoiding smoking were effective in reducing the risk of a
myocardial infarction by 80% [15]. Estimates from a study
by Hopkins suggested that a cholesterol-lowering diet
could reduce LDL-C levels by up to 21% in people with
heterogeneous FH [16]. Clearly, a healthy lifestyle is an as-
pect of the treatment of FH with benefits beyond LDL-C-
lowering drugs [17]. FH treatment should not merely focus
on LDL-C, but also on a larger spectrum of risk factors
[18]. We therefore assumed that raised awareness of the ac-
tual CVD risk, improved lifestyle behaviours and improved
compliance to statin therapy is a promising strategy in re-
ducing CVD risk in people with FH.
In the PRO-FIT project, we developed an individually
tailored lifestyle intervention aimed at a CVD risk re-
duction in individuals with FH. At first, we investigated
the efficacy of the intervention on smoking, physical ac-
tivity, dietary intake and compliance to statin therapy
(Broekhuizen K, Msc, unpublished data, 2011). In this
paper, we report the efficacy on biological CVD risk
indicators: lipids (LDL-C, HDL-C, TC and triglycerides),
systolic blood pressure, glucose, body mass index (BMI)
and waist circumference.
Methods
Design and participants
A randomised controlled trial was conducted with mea-
surements at baseline and at 12 months post-baseline. Par-
ticipants diagnosed with FH from January 1st 2007 to April
15th 2009, aged from 18 to 70 years and with a LDL-C
level> 75th percentile (age and gender specific) were
recruited from the national cascade screening programme
of the Foundation for the Identification of Persons with
Inherited Hypercholesterolemia (StOEH). Access to inter-
net, sufficient fluency in Dutch and residency <150 km ra-
dius from Amsterdam were additional eligibility criteria.
Invitation brochures were send to 986 people, of whom 321
(32%) responded and agreed to participate. An additional
23 participants were recruited through brochures that were
distributed among family members of participants, meetingthe same eligibility criteria. The recruitment period lasted
6 months and resulted in 340 participants. Three hundred
and fifteen participants (93%) attended the baseline and fol-
low-up measurements.
Details on the participant flow can be found in Figure 1.
The content of this paper was guided by the recommen-
dations for reporting randomised controlled trials of the
CONSORT (Consolidated Standards of Reporting Trials)
statement [19]. The ethical principles of the Helsinki
Declaration were followed and the PRO-FIT project was
approved by the Medical Ethics Committee of the VU
University Medical Centre. All participants gave written
informed consent.
Procedure
Participants were randomly assigned to either the no-inter-
vention control group (n= 159) or the intervention group
(n=181) through a stratified computerised randomisation
procedure using Microsoft© Office Access 2003 software.
Randomisation was concealed. At first, participants were
stratified according to cholesterol lowering medication use
(yes/no), assuming that medication use implicates treat-
ment by a general practitioner and/or medical specialist,
who could have already given advice on lifestyle behaviour.
In addition, we expected that a decrease in LDL-C because
of the intervention would be smaller if a participant
already used medication. Family members of the same
household were clustered and subsequently randomised as
a cluster to prevent contamination of the intervention ef-
fect due to spill over of communication about the inter-
vention among family members.
Theoretical framework
The intervention of the PRO-FIT project was developed
according to the integrated model for exploring motiv-
ational and behavioural change, the I-Change model (2.0)
[20,21]. Briefly, it assumes that the behavioural change
process can be distinguished in three phases: 1) Aware-
ness, 2) Motivation and 3) Action. Hypothetically, due to
gained knowledge and awareness of one’s CVD risk, a
participant will become motivated to change lifestyle be-
haviour(s), and subsequently, implementation intentions
and action plans will be formed to actually achieve (main-
tenance of) behavioural change. In addition, it is assumed
that this will eventually lead to a reduction in CVD risk.
The assumed pathway is illustrated in the I-Change
model (2.0) in Figure 2.
Intervention
The intervention consisted of a personalised health coun-
selling intervention; a combination of computer-generated
tailored web-based advice (PRO-FIT*advice) and face-to-
face counselling complemented with telephone booster
sessions (PRO-FIT*coach). The goal was to: 1) improve
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crease of specific knowledge, cues to action and change in
risk perception, 2) improve motivation with respect to
healthy behaviour through an increase of specific know-
ledge and a change in attitude, self-efficacy and socialIntervention Group N=181
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Figure 2 The I-Change model 2.0. The I-Change model assumes that the behavioural change process can be distinguished in three phases: 1)
Awareness, 2) Motivation and 3) Action. Hypothetically, due to gained knowledge and awareness of one’s CVD risk, a participant will become
motivated to change lifestyle behaviour(s), and subsequently, implementation intentions and action plans will be formed to actually achieve
(maintenance of) behavioural change. In addition, it is assumed that this will eventually lead to a reduction in CVD risk.
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where [21]. Briefly, participants were encouraged to visit
a web link referring to the project website, where gen-
eric online CVD risk information was presented, con-
taining feedback on CVD risk behaviours and their
contribution to overall CVD risk, as well as information
on the changeability of these behaviours and cues on
how to change behaviours. Thereafter, participants could
log on to a personal PRO-FIT*advice account, consisting
of six tailored advice modules on smoking, physical ac-
tivity, saturated fat intake, fruit intake, vegetables intake
and compliance to statin therapy. On-screen computer-
generated personalised feedback was tailored to personal
performance level (current lifestyle behaviour), aware-
ness of one’s own performance, as well as personal mo-
tivation to change, outcome expectations, attitude and
self-efficacy. Personalised feedback on compliance to
statin therapy was tailored to knowledge and personal
beliefs about (the effect of ) statin therapy, potential side
effects of the prescribed drug and current compliance.
Subsequently, a month later, the participant and the
personal coach further established the level of the partici-
pant’s knowledge/awareness about FH and cardiovascular
risk factors. Furthermore, the assessment(s) and advice(s)
within the participant’s personal PRO-FIT*advice account
were discussed and ambivalence and barriers related to
the recommended behaviour changes were explored
based on Motivational Interviewing (MI) techniques [22].Further, one to five counsellor-initiated booster telephone
sessions were performed during a period of 9 months to
encourage the participant’s behavioural changes and to
provide further brief motivational interviewing to encour-
age the planned behavioural changes.
The control group received care as usual.
Measurements
In this project, lipids (LDL-C, HDL-C, TC and triglycer-
ides), systolic blood pressure, glucose, BMI and waist cir-
cumference were defined as CVD risk indicators, also
known as classical CVD risk factors, as reported by the
Adult Treatment Panel (ATP) III of the NCEP, that for-
mulated an evidence-based set of guidelines of cholesterol
management for the general population [23]. These clas-
sical risk factors also contribute to the CVD risk in people
with FH [24].
All CVD risk indicators were measured at the partici-
pants’ homes. LDL-C, HDL-C and TC, triglycerides and
glucose were measured with fasting finger stick samples
analysed on a Cholestech LDX desktop analyser (Choles-
tech, Hayward, USA). This portable analyser is capable of
providing a lipid profile and glucose in approximately 5
minutes. The reproducibility and precision of lipids meas-
urement by the LDX analyser are within the guidelines of
the NCEP [25,26]. The Cholestech LDX analyser has
been validated for point-of-care lipid measurements in
clinical practice [27]. Systolic and diastolic blood pressure
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blood pressure monitor (type: Omron M5-I). The mean
value of the two measurements was computed.
Body height (in cm) was measured on bare feet with a
portable device with a wide measuring slide and a heel
plate. Calibrated scales were used to determine body
weight (in kg) while participants wore light clothing only
(e.g. underwear). Both body weight and height were mea-
sured twice, and the mean value of the two measure-
ments was used to calculate BMI. Waist circumference
(in cm) was measured twice with a measurement tape to
the nearest 0.10 cm, at the midpoint between the lower
border of the ribs and the upper border of the pelvis. The
mean value of the two measurements was computed.
A process evaluation was carried out, taking into ac-
count the process elements reach, dose (delivered and
received) and fidelity [28]. In short, reach (the number of
people included in the project, as well as their representa-
tiveness for the study population and non-participants)
was assessed by consulting the StOEH/PRO-FIT client
database. The dose of all delivered elements of the inter-
vention was assessed by logs that were kept by the coaches
and the project database. Dose received, i.e. the way parti-
cipants used PRO-FIT*advice (% of participants that
logged on, number of modules finished), was assessed by
means of log on rates and website use data. Whether face-
to-face counseling sessions were implemented as planned
according to Motivational Interviewing (MI) guidelines (fi-
delity) was assessed by two MI experts, following the MI
Treatment Integrity code 3.1.1 [29]. For this assessment, a
random sample of 20 audio taped counselling sessions (10
sessions of each lifestyle coach; approximately 10% of all
sessions) was drawn. A verbatim transcript [30] of each
drawn session was evaluated and resulted in two scores: a
global score, capturing an overall impression of the con-
versation on a 5-point Likert scale on the following 5
dimensions: Evocation, Collaboration, Autonomy/Support,
Direction and Empathy. In addition, specific behaviours of
the lifestyle coach, such as the number of open/closed
questions and simple/complex reflections (reflective state-
ments made by the counsellor in response to participant,
without/with additional meaning or emphasis to what the
participant has said) were counted. Counselling sessions
were considered MI if the average of global scores was≥
3.5, reflection to question ratio was in favour of reflection,
>50% of the questions were open questions, >40% of the
reflections were complex reflections and >90% of all utter-
ances was MI-adherent [29].
Statistical analyses
Potential baseline differences were checked between inter-
vention and control group, regarding gender, age, educa-
tion, BMI, medication use and LDL-C. In case of baseline
differences between intervention and control group, theconcerned covariate was included in the analyses. In
addition, differences between dropouts and participants
regarding the above-mentioned baseline characteristics
were tested by linear regression analyses.
Primary, a complete case analysis was conducted at the
participant level, restricted to those who attended baseline
and follow-up measurements. These numbers vary for dif-
ferent outcome measures. Subsequently, an intention-to-
treat analysis was conducted, involving all participants
who were randomly assigned (n= 340). Missing data on
lipids (LDL-C, HDL-C, TC and triglycerides), systolic
blood pressure, glucose, BMI and waist circumference
were imputed using multiple imputations. Five different
datasets were created in SPSS (version 18.0) using Fully
Conditional Specification and Predictive Mean Matching
procedures. All available data on the above-mentioned
outcomes, as well as on group allocation, gender, age, edu-
cation, BMI, medication use and LDL-C were included in
the imputation model. Thereafter the multiple datasets
were analysed as described below, using SPSS (version
18.0). Pooled estimates were computed following the rules
as described by Rubin [31]. As no major differences were
found, only the results of the complete case analysis are
presented.
In order to investigate whether this intervention had an
effect on lipids (LDL-C, HDL-C, TC and triglycerides),
systolic blood pressure, glucose, BMI and waist circum-
ference, linear regression analyses were conducted to de-
tect between group differences after 12 months (two-
sided; significance level 0.05). The post-test scores were
regressed on study group and baseline measure of the
outcome variable.
Results
Baseline characteristics of participants
In Figure 1 the recruitment, participant and retention
flow is presented. As can be seen from Table 1, the parti-
cipants were equally distributed with regard to gender.
Overall, a mainly middle aged, medium to highly edu-
cated, fairly overweight and the majority has an elevated
LDL-C and used cholesterol-lowering medication. Base-
line differences between the control and intervention
group were found for BMI (β=−1.10; CI −2.17- −0.04).
As a consequence, this variable was included in the re-
gression analyses as a potential confounder. No differ-
ences were found between dropouts and participants
regarding the baseline characteristics.
Effect on biological risk indicators
After 12 months, LDL-C had decreased in both the
intervention and control group (see Table 2). No signifi-
cant between-group difference was found, as well as for
HDL-C, TC, triglycerides, systolic blood pressure, glu-
cose, BMI and waist circumference. Both groups showed
Table 1 Baseline characteristics of the control and
intervention group
Control group Intervention group
Gender (% female; N) 56.3; N = 159 57.1; N = 181
Age (years, mean± SD; N) 45.9 (13.0); N = 159 44.7 (12.9); N = 181
Education (%; N)
low
medium
high
3.6
62.8
33.6; N = 137
3.1
58.2
38.7; N = 163
BMI (kg/m2, mean± SD; N) 27.1 (5.3); N =159 26.0 (4.7); N = 181
Medication use (% yes; N) 69.6; N = 159 68.8; N = 181
LDL-C (mmol/l, mean± SD; N) 3.7 (1.2); N = 130 3.7 (1.3); N = 146
N= sample size; SD = standard deviation; BMI = body mass index; Significant
differences between control and intervention group (P< 0.05) are printed in
bold font.
Table 2 Biological CVD risk indicators at baseline and
follow-up and intervention effects from linear regression
analyses, based on a complete-case analysis*
Control
group
Intervention
group
beta 95% CI
LDL-C (mmol/l, mean± SD)
Baseline
12 months
Difference
N= 105
3.7 (1.2)
3.6 (1.2)
−0.1
N= 128
3.6 (1.3)
3.5 (1.1)
−0.1
−0.20 −0.40-0.03
HDL-C (mmol/l, mean± SD)
Baseline
12 months
Difference
N= 143
1.2 (0.4)
1.2 (0.4)
0
N= 169
1.2 (0.4)
1.2 (0.4)
0
0.02 −0.04-0.08
TC (mmol/l, mean± SD)
Baseline
12 months
Difference
N= 146
5.2 (1.2)
5.1 (1.2)
−0.1
N= 169
5.3 (1.4)
5.2 (1.2)
−0.1
−0.04 −0.25-0.18
Triglycerides
(mmol/l, mean± SD)
Baseline
12 months
Difference
N= 110
1.3 (0.7)
1.2 (0.6)
−0.1
N= 128
1.2 (0.6)
1.3 (0.7)
+0.1
0.08 −0.08-0.23
Systolic blood pressure
(mmHg, mean± SD)
N = 143 N= 169
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and glucose. A minor increase of triglycerides was seen
in the intervention group, in contrast to a decrease in
the control group. In the control group, no change in
BMI was observed after 12 months, compared to a de-
crease in the intervention group. Waist circumference
did not change in the control group and decreased in
the intervention group.Baseline
12 months
Difference
126.3 (15.7)
125.2 (14.4)
−1.1
123.0 (14.4)
123.0 (14.1)
0
0.003 −2.28-2.28
Glucose (mmol/l, mean± SD)
Baseline
12 months
Difference
N= 145
4.9 (1.0)
4.8 (0.8)
−0.1
N= 169
4.9 (0.8)
4.7 (0.7)
−0.2
−0.06 −0.19-0.07
BMI (kg/m2, mean± SD)
Baseline
12 months
Difference
N= 147
27.1 (5.4)
27.1 (5.2)
0
N= 167
25.9 (4.5)
25.8 (4.4)
−0.1
−0.18 −0.43-0.07
Waist circumference
(cm, mean± SD)
N = 146 N= 165Process
A 34% (n = 181) representative proportion of the
intended intervention group was reached during the re-
cruitment phase; participants did not differ from non-
participants (n = 623) in the StOEH client database on
age, gender and LDL-C levels. Of the participants, 95%
received a PRO-FIT*advice log on account, of which 49%
actually logged on and completed at least one advice
module. Nearly all participants received a face-to-face
counseling session and on average, 4.2 telephone booster
calls were delivered. None of the face-to-face sessions
were implemented according to MI guidelines.Baseline
12 months
Difference
89.9 (14.5)
89.9 (14.3)
0
86.4 (11.9)
86.1 (11.5)
−0.3
−0.54 −1.45-0.40
*Differences between control and intervention group after 12 months are
tested through linear regression analyses, controlled for baseline values and
baseline BMI. Beta = unstandardised regression coefficient; N = sample size;
SD = standard deviation; 95% CI = 95% confidence interval as effect indicator
from linear regression analyses; Means presented are from unadjusted
analyses; Significant differences between control and intervention group
(P< 0.05) printed in bold font. Only the results of the complete case analysis
are presented, since no major differences were found between intention-to-
treat analysis and complete case analysis.Discussion
In this paper, the efficacy of an individually tailored life-
style intervention on lipids (LDL-C, HDL-C, TC and tri-
glycerides), systolic blood pressure, glucose, BMI and
waist circumference in people with FH was investigated.
After 12 months, LDL-C levels had decreased in both the
intervention and control group. This difference between
intervention and control group was not statistically sig-
nificant. Furthermore, the LDL-C concentrations in both
groups did not result in reaching the recommended treat-
ment target concentration of ≤2.5 mmol/l for most parti-
cipants [32]. Based on a comparable population, Huijgen
and colleagues also concluded that only a minority of the
medication users reaches LDL-C treatment targets within
two years after screening [33].Overall, we also did not observe any significant inter-
vention effects on HDL-C, TC, triglycerides, systolic
blood pressure, glucose, BMI and waist circumference.
However, it may be that the collective contribution of
all these small improvements together is cumulative,
and larger than the CVD risk reduction associated with
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prediction tool is available for FH populations, it is im-
possible to have an accurate estimate of the CVD risk
reduction from all the small improvements together.
Such a CVD risk prediction tool would be beneficial
for the interpretation of our results. Moreover, it would
be possible to identify people with severely increased
CVD risk. Several CVD risk estimates are available,
such as the risk assessment tool that uses data from
the Framingham Heart Study to estimate 10-year risk
for hard coronary heart disease outcomes [34]. How-
ever, these tools are based on calculations in a non-FH
reference population, and it is known that classical risk
factors in a FH population do not necessarily play the
same role with the same intensity [24]. Civeira pro-
posed a risk assessment tool, dividing people with FH
in three risk categories: low-moderate-high 10 year
CVD mortality risk [17]. However, lipoprotein-A and
carotid intima media thickness, defined as major risk
factors by Civeira, were not assessed in this project.
Participants who were not on statin treatment had not-
ably higher LDL-C and TC levels at baseline, and accord-
ing to post-hoc analyses, reductions in LDL-C and TC
concentrations were most obvious among participants
who used no statins (data not shown). Clearly, a reduc-
tion in lipids levels is most expected among this sub-
sample, since more reduction of lipid levels can be
achieved. However, due to the small subsample (n = 72),
this finding should be interpreted with great caution.
We did not find any significant intervention effects on
all targeted lifestyle behaviours in the PRO-FIT project
(data not shown). We can not confirm nor reject
whether small improvements of biological CVD indica-
tors were caused by behavioural improvements. The lack
of intervention effects on biological CVD risk indicators
and lifestyle behaviours found in the PRO-FIT project
are not in accordance with the latest evidence, as in a
literature review, Blokstra et al. showed that multifactor-
ial lifestyle interventions could have favorable effects
among individuals with a high CVD risk: improvements
in blood pressure (−2-4 mmHg), nutrition, physical ac-
tivity and smoking (−25-40%) were found [14]. Studies
on other high-risk populations also showed that bio-
logical changes can be achieved, though often small and
not significant at a long term (> 6 months) [35,36].
However, the above-mentioned studies did not include
FH subjects. In a recent review of Shafiq (2011), no dif-
ferences were reported between cholesterol-lowering
diet in comparison with no intervention or other dietary
interventions in people with FH [37].
It may be that the intervention reach and dose received
were insufficient to initiate behaviour changes and, subse-
quently, changes in CVD indicators. Our process evalu-
ation indicates that participants were sufficiently exposedto the intervention. However, only half of the participants
logged on at the PRO-FIT*advice website and completed
at least one of the advice modules, and face-to-face coun-
selling sessions were delivered with low MI fidelity.
More in-depth analysis showed weak and positive asso-
ciations between dose and LDL-C change for all inter-
vention components (data not shown). Due to the small
sample of audio taped sessions (n = 20), the association
between MI fidelity and efficacy could not be tested in
this study, but previous studies showed that a better MI
performance is associated with larger intervention
effects [22,38]. Also, mixed evidence has been published
on computer-tailored interventions addressing more
than one lifestyle behaviour. It is possible that multiple-
behaviour interventions may be burdensome for some
individuals, and advices may be too long [39-41]. Over-
all, it is possible that the poor MI fidelity and dose of
PRO-FIT*advice received contributed to the lack of effi-
cacy. Probably, the provided MI workshop was not suffi-
cient and more thorough monitoring and supervision of
counselling skills during the intervention should have
been built in, as it has often been reported that skills
required for effective MI may take longer to develop
than the 3-day MI workshop in our project [42,43].
The strengths of this project include the randomised
design, which avoided study contamination that could
have resulted from individual changes of participants in
both intervention and control group. To our knowledge,
the PRO-FIT intervention is the first to evaluate the
effects of a lifestyle intervention on multiple lifestyle
behaviours and CVD risk indicators among people with
FH. The RCT was conducted in a sample representative
for the screened FH population in the Netherlands with
a small dropout rate. However, the recruitment rate of
our study was only 34% and contained a self-selected
sample of mainly medium-educated participants with
internet access and sufficient fluency in Dutch. Although
no differences on age, gender and LDL-C levels were
found between participants and non-participants, our
sample could have been more motivated to change life-
style behaviour, which might limit the generalisability of
our findings [44].
While various unhealthy lifestyle factors are related to
the atherosclerotic process, it is the long-term exposure
that leads to the clinical manifestations of cardiovascular
events [45]. Vice versa, the effect of lifestyle improve-
ments is likely to lead to CVD risk reduction only at the
longer term. Inclusion of more long-term follow-up mea-
surements in future RTCs on the efficacy of lifestyle
interventions is to be recommended, since it would shed
more light on possible effects on CVD risk and hard out-
comes (e.g. CVD/death).
Altogether, it remains unclear how genetic and lifestyle
factors interact in the FH population. FH is a monogenetic
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suggesting that environmental factors play an important
role as well. Whether the gene-environment interactions
are synergistic or simply additive remains to be revealed. It
would be informative to conduct a trial similar to the
PRO-FIT project with the inclusion of a non-FH control
group with elevated LDL-C levels. Despite the unknown
interactions, the primary goal of treatment of people with
FH should be considered as invariable: achieving optimal
CVD risk reduction.
In conclusion, this project suggests that an individually
tailored lifestyle intervention is not superior to usual
care, regarding changes in LDL-C levels in people with
FH. A small CVD risk reduction might result from the
generally slight improvements of all the CVD risk indica-
tors. However, in order to draw conclusions on impact
of the cumulative effect of all these small improvements,
and thus on the efficacy of lifestyle improvements in a
FH population, more RCTs should be performed, includ-
ing more long-term objective measurements (of e.g. ca-
rotid intima thickness and lipoprotein A) and long-term
monitoring of CVD-related morbidity and mortality.Conclusions
An individually tailored lifestyle intervention did not
have an additional effect in reducing LDL-C levels
among people with FH. The cumulative effect of many
small improvements in all CVD risk factors on long term
CVD risk remains to be assessed in future studies.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements and funding
We would like to acknowledge the patient organisation for people with
(inherited) CVD (in Dutch: Hart & Vaatgroep/StichtingBloedlink) for initiating
this project, and the Cascade screening programme of the Dutch Foundation
for the Identification of Persons with Inherited Hypercholesterolemia (in
Dutch: StOEH) for their support regarding the recruitment of participants. We
are grateful to Dr. A. Oenema of the Erasmus University Medical Centre in
Rotterdam, the Netherlands and prof. Dr. A. Dijkstra of the Rijksuniversiteit
Groningen, the Netherlands, for sharing their computer-tailored advice
modules. This work was supported by the Netherlands Organisation for
Health, Research and Development (ZonMw) [50-50110-96-489].
Author details
1Department of Public and Occupational Health, EMGO+Institute for Health
and Care Research, VU University Medical Center, room G0.30, P.O. Box 7057,
1007 MB Amsterdam, The Netherlands. 2TNO Quality of Life, Division Work
and Employment, Hoofddorp, The Netherlands. 3Foundation for the
Identification of Persons with Inherited Hypercholesterolemia (StOEH),
Amsterdam, The Netherlands. 4Department of Epidemiology and Biostatistics,
EMGO+Institute for Health and Care Research, VU University Medical Centre,
Amsterdam, The Netherlands.
Authors’ contributions
KB was responsible for data analysis, interpretation and reporting, while MvP,
LK, IK, JB and WvM assisted in interpreting and reporting. All authors read,
edited and approved the final version of the manuscript.Received: 6 December 2011 Accepted: 10 April 2012
Published: 10 April 2012References
1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson DL, et al:
Harrison’s principles of internal medicine. 17th edition. New York: McGraw-Hill
Medical Publishing Division; 2008.
2. Goldstein J, Hobbs H, Brown M: Familial Hypercholesterolemia. In The
Metabolic and Molecular Bases of Inherited Disease. Edited by Scriver C,
Beaudet A, Sly WVD. New York: McGraw-Hill; 2001:2863–2913.
3. Risk of fatal coronary heart disease in familial hypercholesterolaemia:
Scientific steering committee on behalf of the simon broome register
group. BMJ 1991, 303:893–896.
4. Treurniet HF, Hoeymans N, Gijsen R, Poos MJ, van Oers JA, Thien WM:
Health status and the challenges for prevention in The Netherlands.
Public Health 2005, 119:159–166.
5. Yuan G, Wang J, Hegele RA: Heterozygous familial hypercholesterolemia:
an underrecognized cause of early cardiovascular disease. CMAJ 2006,
174:1124–1129.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al:
Efficacy and safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised trials of
statins. Lancet 2005, 366:1267–1278.
7. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al: Efficacy of
cholesterol-lowering therapy in 18,686 people with diabetes in 14
randomised trials of statins: a meta-analysis. Lancet 2008, 371:117–125.
8. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem
AH, et al: Efficacy of statins in familial hypercholesterolaemia: a long term
cohort study. BMJ 2008, 337:a2423.
9. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al: The
Residual Risk Reduction Initiative: a call to action to reduce residual
vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K–34K.
10. Hegele RA: Environmental modulation of atherosclerosis end points in
familial hypercholesterolemia. Atheroscler Suppl 2002, 2:5–7.
11. Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial
hypercholesterolemia and coronary heart disease: a HuGE association
review. Am J Epidemiol 2004, 160:421–429.
12. Kotseva K, Wood D, Backer GD, Bacquer DD, Py+Âr+ñl+ñ K, Keil U et al.:
EUROASPIRE III: a survey on the lifestyle, risk factors and use of
cardioprotective drug therapies in coronary patients from 22 European
countries. J Cardiovascular Risk 2009, 16:121–137.
13. Kromhout D, Menotti A, Kesteloot H, Sans S: Prevention of coronary heart
disease by diet and lifestyle: evidence from prospective cross-cultural,
cohort, and intervention studies. Circulation 2002, 105:893–898.
14. Blokstra A, van D, I, Verschuren WM: Efficacy of multifactorial lifestyle
interventions in patients with established cardiovascular diseases and
high risk groups. Eur J Cardiovasc Nurs 2012, 11:97–104.
15. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al: Effect of
potentially modifiable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study): case–control study. Lancet 2004,
364:937–952.
16. Hopkins PN: Familial hypercholesterolemia–improving treatment and
meeting guidelines. Int J Cardiol 2003, 89:13–23.
17. Civeira F: Guidelines for the diagnosis and management of heterozygous
familial hypercholesterolemia. Atherosclerosis 2004, 173:55–68.
18. Fouchier SW, Rodenburg J, Defesche JC, Kastelein JJ: Management of
hereditary dyslipidaemia; the paradigm of autosomal dominant
hypercholesterolaemia. Eur J Hum Genet 2005, 13:1247–1253.
19. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: Updated
guidelines for reporting parallel group randomised trials. J Clin Epidemiol
2010, 63:834–840.
20. De Vries H, Mesters I, Riet JV, Willems K, Reubsaet A: Motives of Belgian
adolescents for using sunscreen: the role of action plans. Cancer
Epidemiol Biomarkers Prev 2006, 15:1360–1366.
21. Broekhuizen K, van Poppel M, Koppes L, Kindt I, Brug J, van Mechelen W:
Can multiple lifestyle behaviours be improved in people with Familial
Hypercholesterolemia? Results of a randomised controlled trial. Int J
Behav Nutr Phys Act 2011, Submitted.
22. Rubak S, Sandbaek A, Lauritzen T, Christensen B: Motivational interviewing:
a systematic review and meta-analysis. Br J Gen Pract 2005, 55:305–312.
Broekhuizen et al. BMC Research Notes 2012, 5:181 Page 9 of 9
http://www.biomedcentral.com/1756-0500/5/18123. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel
III). JAMA 2001, 285:2486–2497.
24. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH,
et al: The contribution of classical risk factors to cardiovascular disease in
familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004,
256:482–490.
25. Issa JS, Strunz C, Giannini SD, Forti N, Diament J: Precision and accuracy of
blood lipid analyses by a portable device (Cholestech-LDX). Arq Bras
Cardiol 1996, 66:339–342.
26. Panz VR, Raal FJ, Paiker J, Immelman R, Miles H: Performance of the
CardioChek PA and Cholestech LDX point-of-care analysers compared to
clinical diagnostic laboratory methods for the measurement of lipids.
Cardiovasc J S Afr 2005, 16:112–117.
27. Carey M, Markham C, Gaffney P, Boran C, Maher V: Validation of a point of
care lipid analyser using a hospital based reference laboratory. Ir J Med
Sci 2006, 175:30–35.
28. Linnan L, Steckler A: Process Evaluation for Public Health Interventions
and Research. Edited by Linnan L, Steckler A. San Francisco: Jossey-Bass;
2002:1–24.
29. Moyers TB, Martin T, Manual JK, Miller WR, Ernst D: Revised Global Scales:
Motivational Interviewing Treatment Integrity 3.0 (MITI 3.0). 28. 2007.
University of New Mexico, Center on Alcoholism, Substance Abuse and
Addictions (CASAA). Ref Type: Unpublished Work
30. Halcomb EJ, Davidson PM: Is verbatim transcription of interview data
always necessary? Appl Nurs Res 2006, 19:38–42.
31. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York: J Wiley
& Sons; 1987.
32. Walma E, Wiersma Tj: NHG-Standpunt Diagnostiek en behandeling van
familiaire hypercholesterolemie. Huisarts Wet 2006, 49:202–204.
33. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, et al:
Two years after molecular diagnosis of familial hypercholesterolemia:
majority on cholesterol-lowering treatment but a minority reaches
treatment goal. PLoS One 2010, 5:e9220.
34. Viera AJ, Sheridan SL: Global risk of coronary heart disease: assessment
and application. Am Fam Physician 2010, 82:265–274.
35. Kroeze W, Dagnelie PC, Heymans MW, Oenema A, Brug J: Biomarker
evaluation does not confirm efficacy of computer-tailored nutrition
education. J Nutr Educ Behav 2011, 43:323–330.
36. Groeneveld IF, Proper KI, van der Beek AJ, Hildebrandt VH, van MW: Short
and long term effects of a lifestyle intervention for construction workers
at risk for cardiovascular disease: a randomized controlled trial. BMC Publ
Health 2011, 11:836.
37. Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S: Dietary treatment for
familial hypercholesterolaemia. Cochrane Database Syst Rev 2010, 1:
CD001918.
38. Kreman R, Yates BC, Agrawal S, Fiandt K, Briner W, Shurmur S: The effects of
motivational interviewing on physiological outcomes. Appl Nurs Res 2006,
19:167–170.
39. Carlson JA, Sallis JF, Ramirez ER, Patrick K, Norman GJ: Physical activity and
dietary behavior change in Internet-based weight loss interventions:
Comparing two multiple-behavior change indices. Prev Med 2012, 54:50–54.
40. Noar SM, Chabot M, Zimmerman RS: Applying health behavior theory to
multiple behavior change: considerations and approaches. Prev Med 2008,
46:275–280.
41. Prochaska JJ, Spring B, Nigg CR: Multiple health behavior change research:
an introduction and overview. Prev Med 2008, 46:181–188.
42. Britt E, Hudson SM, Blampied NM: Motivational interviewing in health
settings: a review. Patient Educ Couns 2004, 53:147–155.
43. Levensky ER, Forcehimes A, O’Donohue WT, Beitz K: Motivational
interviewing: an evidence-based approach to counseling helps patients
follow treatment recommendations. Am J Nurs 2007, 107:50–58.
44. Dzewaltowski DA, Estabrooks PA, Klesges LM, Bull S, Glasgow RE: Behavior
change intervention research in community settings: how generalizable
are the results? Health Promot Int 2004, 19:235–245.
45. Haskell WL: Cardiovascular disease prevention and lifestyle interventions:
effectiveness and efficacy. J Cardiovasc Nurs 2003, 18:245–255.
46. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ:
Mortality over two centuries in large pedigree with familial
hypercholesterolaemia: family tree mortality study. BMJ 2001, 322:1019–1023.doi:10.1186/1756-0500-5-181
Cite this article as: Broekhuizen et al: No significant improvement of
cardiovascular disease risk indicators by a lifestyle intervention in
people with Familial Hypercholesterolemia compared to usual care:
results of a randomised controlled trial. BMC Research Notes 2012 5:181.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
